04191 Inhibition of glycine transporter 1 reduces EPP phototoxicity in a mouse model of erythropoietic protoporphyria (EPP)

Yi Xiang, Yue Chen, Scott A. Reisman, Srikanth Venkatraman, Hua Yang, Brian MacDonald, Min Wu2024 · DOI

This summary focuses on the research abstract 04191: Inhibition of glycine transporter 1 reduces EPP phototoxicity in a mouse model of erythropoietic protoporphyria (EPP), presented by researchers from Disc Medicine.

TL;DR

Researchers have demonstrated that inhibiting Glycine Transporter 1 (GlyT1) significantly reduces the accumulation of light-sensitive protoporphyrin IX (PPIX) in red blood cells. In a mouse model of Erythropoietic Protoporphyria (EPP), this intervention successfully mitigated the severe skin damage (phototoxicity) typically triggered by light exposure, highlighting a promising new systemic therapeutic approach.

What Problem Does This Paper Address?

Erythropoietic Protoporphyria (EPP) is a rare genetic disorder caused by a deficiency in ferrochelatase (FECH), the enzyme responsible for the final step of heme biosynthesis. This deficiency leads to a massive buildup of Protoporphyrin IX (PPIX) in red blood cells.

PPIX is highly "phototoxic"—when exposed to specific wavelengths of light (sunlight), it absorbs photons and generates reactive oxygen species (ROS). These ROS cause immediate, excruciating pain and subdermal skin damage. Currently, patients have very few treatment options and must often live in near-total avoidance of sunlight. This study investigates whether "starving" the heme pathway of its precursors can prevent PPIX buildup at the source.

Methods

The researchers targeted Glycine Transporter 1 (GlyT1), which is responsible for importing glycine—a critical building block for heme—into erythroid cells.

  • Animal Model: They used $Fech^{m1Pas}/Fech^{m1Pas}$ homozygous mice, which retain only ~5% of normal FECH activity, closely mimicking the human EPP phenotype.
  • The Intervention: Mice were treated with DISC-C, a selective small-molecule inhibitor of GlyT1, administered orally (15 mg/kg) twice daily for 18 days.
  • The Challenge: On Day 14, the mice's hair was removed, and they were exposed to 395 nm light (the excitation wavelength for PPIX) at 588 lumens/m² for 30 minutes.
  • Metrics: The team measured PPIX levels in red blood cells (RBCs) and quantified the percentage of skin area affected by lesions.

Datasets

As a laboratory animal study, this paper does not use traditional computational datasets. Instead, it utilizes a specialized biological model: the $Fech^{m1Pas}$ mouse model, a validated benchmark for EPP research that develops elevated PPIX, liver fibrosis, and cutaneous phototoxicity.

Key Insights and Ideas

  • Throttling the Precursor: The core idea is that by inhibiting GlyT1, you create a "bottleneck" for glycine. Since glycine is a necessary precursor for heme synthesis, reducing its availability limits the production of PPIX, even when the downstream FECH enzyme is broken.
  • Direct Correlation: The study confirmed a strong correlation between lower PPIX levels in RBCs and a lower percentage of skin lesions. This validates RBC PPIX as a reliable surrogate biomarker for clinical phototoxicity.
  • Systemic vs. Topical: Unlike sunscreens or physical barriers, this approach is systemic, treating the underlying biochemical imbalance that makes the blood itself "toxic" to light.

Key Results

  • PPIX Reduction: Treatment with DISC-C reduced PPIX levels in RBCs by 43% on Day 14 and 37% on Day 18 compared to the control group.
  • Photoprotection: The results of the light challenge were stark. Mice given the vehicle (control) developed worsening lesions, with 51.2% of the exposed skin area showing damage by Day 18.
  • Efficacy of DISC-C: Mice treated with the GlyT1 inhibitor developed lesions on only 9.2% of the exposed skin area—a massive reduction in clinical severity.

Limitations and Future Work

  • Mouse to Human Translation: While the $Fech^{m1Pas}$ model is robust, human heme metabolism and skin thickness differ from mice. However, the authors note that GlyT1 inhibitors like bitopertin have already shown PPIX reduction in Phase 2 human clinical trials.
  • Long-term Effects: The study lasted 18 days. Because EPP is a lifelong condition, future research will need to address the long-term safety of chronic GlyT1 inhibition, particularly regarding potential impacts on overall heme production (e.g., anemia).
  • Optimal Dosing: Further studies are likely needed to find the "sweet spot" of GlyT1 inhibition that maximizes photoprotection while maintaining healthy hemoglobin levels.

Summary updated

Abstract

This study investigates the mental health challenges across the Porphyrias through focus group discussions.The primary aim was to identify emotional and psychological issues, coping strategies, and support needs.Both groups reported significant mental health struggles.Recommendations include enhanced mental health support, mentorship programs, and communitybuilding initiatives to improve the quality of life for those affected by porphyria.Methods Focus groups were conducted for individuals with Cutaneous Porphyria on May 13, 2024, and Acute Hepatic Porphyria on June 13, 2024.Discussions covered mental health struggles, coping strategies, and the impact of the disease on daily life.The sessions were transcribed and analyzed to identify recurring themes and key takeaways.
BibTeX
@misc{xiang2024inhibition,
  author = {Yi Xiang and Yue Chen and Scott A. Reisman and Srikanth Venkatraman and Hua Yang and Brian MacDonald and Min Wu},
  title = {{04191 Inhibition of glycine transporter 1 reduces EPP phototoxicity in a mouse model of erythropoietic protoporphyria (EPP)}},
  year = {2024},
  doi = {10.1136/bmjgast-2024-icpp.32},
}
Figure